NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) — According to a new research report titled “Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by P&S Market Research, Wnt signaling pathway inhibitors currently exhibits a growing pipeline with approximately 26 drug candidates.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/wnt-signaling-pathway-inhibitors-therapeutics-pipeline-analysis/report-sample
The study analyzed that the Wnt signaling pathway inhibitors therapeutics pipeline comprises approximately 26 drug candidates in different stages of development. Wnt or β-Catenin signaling pathway plays an important role in the development of pluripotent cells. The signaling pathway was earlier named as Wingless (Wng) in Drosophila and Int1 in the mouse. Wnt proteins consist of several glycoproteins that have conserved cysteine residues. There are 19 human Wnt genes that encode spliced isoforms. Wnt proteins bind to the Frizzled (Fz) receptors which forms the complex with low-density lipoprotein receptor-related protein (LRP).
According to the research findings, most of the drug candidates of the Wnt signaling pathway inhibitors are being developed as the small molecule. According to the Center for Disease Control and Prevention (CDC), more than 1.5 million cases of invasive cancer, including about 15,000 cases among children younger than 20 years, and more than 590,000 deaths from cancer, are reported every year in the U.S. The rising prevalence of cancer is a major factor driving the pipeline, since Wnt signaling pathway has been recognized in the development of cancer cells.
In July 2017, Oncology Venture AB and 2X Oncology, Inc. entered into an exclusive global license agreement with Eisai Inc. for Eisai’s Phase II PARP inhibitor E7449 – now called 2X-121. 2X-121 would be developed by 2X Oncology, Inc., a precision medicine company developing targeted therapeutics to address significant unmet needs in women’s cancer.
Some of the key players developing drugs for the treatment of Wnt signaling pathway inhibitors therapeutics include Samumed, LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics, Inc. and others.
Browse Related Reports:
Ewing Sarcoma Therapeutics Pipeline Analysis 2017
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc.
Systemic Lupus Erythematosus Pipeline Analysis 2017
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues.
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
P&S Market Research
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)